IGF::OT::IGF CORE INFRASTURCTURE SUPPORT FOR SURVEILLANCE, EPIDEMIOLOGY AND END RESULTS (SEER)PERIOD OF PERFORMANCE: 05/01/2015 TO 04/30/2017

IGF::OT::IGF 对监测、流行病学和最终结果 (SEER) 的核心基础设施支持 执行期间：2015 年 5 月 1 日至 2017 年 4 月 30 日

• 批准号: 9361179
• 负责人: ANTOINETTE STROUP
• 金额: $ 104.99万
• 依托单位: RBHS -CANCER INSTITUTE OF NEW JERSEY
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-05-01 至 2017-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9361179
• 关键词: Cancer Burden; Cancer Control; Cancer Etiology; Cancer Patient; Diagnosis; Disease; Incidence; Malignant Neoplasms; Medical Surveillance; Monitor; National Cancer Institute; National Cancer Program; Patients; Performance; Population; Reporting; Resources; SEER Program; Social Characteristics; Subgroup; Time; Treatment-Related Cancer; United States; base; cancer risk; cancer therapy; operation; response; trend

The SEER Program was initiated in 1972 in response to requirements of the National Cancer Program for assessing the magnitude of the cancer burden in the United States, and for identifying factors related to cancer risk and/or patient survival. The SEER Program has among its objectives: 1. To assemble and report, on a periodic basis, estimates of cancer incidence. 2. To monitor annual cancer incidence trends to identify unusual changes in specific forms of cancer occurring in population subgroups defined by geographic, demographic, and social characteristics. 3. To provide continuing information on changes over time in extent of disease at diagnosis, trends in therapy, and changes in cancer patient survival. 4. To identify the occurrence of possible iatrogenic cancers, i.e., cancers that are caused by cancer therapy. 5. To serve as a research resource to the National Cancer Institute, and conduct studies dealing with current cancer control issues as well as problems related to the operation of the SEER Program.

SEER计划于1972年启动，以响应国家癌症计划的要求，评估美国癌症负担的程度，并确定与癌症风险和/或患者生存相关的因素。SEER方案的目标包括： 1. 定期收集和报告癌症发病率的估计数。 2. 监测年度癌症发病率趋势，以确定由地理、人口统计学和社会特征定义的人群亚组中发生的特定癌症形式的异常变化。 3. 提供关于诊断时疾病程度随时间变化、治疗趋势和癌症患者生存率变化的持续信息。 4. 确定可能的医源性癌症的发生率，即，由癌症治疗引起的癌症。 5. 作为国家癌症研究所的研究资源，并进行研究，处理当前的癌症控制问题以及与SEER计划的运作有关的问题。